SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Judy Muldawer who wrote (6029)2/2/1999 12:45:00 PM
From: Oliver & Co   of 6136
 
"'Triple Cocktail' Hope in AIDS Fight"
Financial Times (02/02/99) P. 10; Pilling, David
New data suggest that triple-drug therapy without protease
inhibitors is as effective in the suppression of HIV viral load
as triple-drug therapies that contain them, according to the
Atlantic study, which was conducted by European and U.S.
universities. Protease inhibitors may have severe adverse
effects, such as unusual fat deposits, in patients who take the
drugs for long-periods of time. The results of the study were
presented at an annual conference on retroviruses in Chicago.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News